Journal
IMMUNOLOGY
Volume 167, Issue 4, Pages 471-481Publisher
WILEY
DOI: 10.1111/imm.13573
Keywords
cancer research; drug development; PD-1; PD-L1; post-translational modification; tumour immunotherapy
Categories
Funding
- National Natural Science Foundation of China [82030077, 8192913]
- Natural Science Foundation of Jiangsu Province [BK20190821]
- China Postdoctoral Science Foundation [2019 M651953, 2021 T140496]
- Jiangsu Postdoctoral Research Foundation [2021K627C]
- Open Project Program of the State Key Laboratory of Radiation Medicine and Protection [GZK1201909]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
The PD-L1/PD-1 signaling pathway is considered one of the main mechanisms of tumor escape from immune surveillance. PD-L1 is highly expressed on tumor cells and binds to the PD-1 receptor on activated T cells, inhibiting their anti-tumor activity. Recent research has focused on post-translational modifications of PD-L1/PD-1, such as glycosylation, ubiquitination, phosphorylation, and acetylation, and their potential role in regulating the signaling pathway and anti-tumor function of T cells.
The immune checkpoint programmed death receptor 1 (PD-1) and programmed death ligand 1 (PD-L1) are biologically important immunosuppressive molecules, and the PD-L1/PD-1-mediated signalling pathway is currently considered one of the main mechanisms of tumour escape immune surveillance. PD-L1 is highly expressed on the cytomembrane of tumour cell and binds to PD-1 receptor of activated T cells. This interaction activates PD-L1/PD-1 downstream signal transduction, inhibiting T cells anti-tumour activity. Therefore, inhibitors of PD-L1/PD-1 activation, showing significant efficacy in some types of tumours, have been widely approved in clinical tumour therapy. Recent research on PD-L1/PD-1 signalling pathway regulation has shown post-translational modifications (PTMs) form of PD-L1 or PD-1, including glycosylation, ubiquitination, phosphorylation, and acetylation, which may play an important role in PD-L1/PD-1 signalling pathway regulation and anti-tumour function of T cells. In this review, we focused on PTMs of PD-L1/PD-1 research and potential applications in tumour immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available